Document series
Trial abstracts — page 12
700 structured trial abstracts. Each is one document in five parts: abstract, design and population, results, certainty assessment and citing documents.
Showing 0 records on this page
Trial records
700 documents · page 12 of 30
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| STEP-HFpEF-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| STEP-HFpEF-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-2-DDIprogramme record | Tirzepatide | Phase 1 | Reported | Randomised crossover | — | 2023 | Very low |
| SURMOUNT-2-HEPATIC-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-2-PKprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-2-RENAL-IMPprogramme record | Tirzepatide | Phase 1 | Reported | Phase 1 ascending dose | — | 2023 | Very low |
| SURMOUNT-3-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-3-QOLprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| SURMOUNT-3-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| CELIAC-PH3-CEDLARA-BODY-COMPprogramme record | Larazotide acetate | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| CELIAC-PH3-CEDLARA-REGIONAL-JPprogramme record | Larazotide acetate | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| MMPOWER-3-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Observational | — | 2022 | Very low |
| MMPOWER-3-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| MMPOWER-3-OLEprogramme record | SS-31 (elamipretide) | Phase 3 | Reported | Single-arm open-label | — | 2022 | Very low |
| STEP-5-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2022 | Very low |
| STEP-5-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-5-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-5-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-8-BIOMARKERprogramme record | Semaglutide | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2022 | Very low |
| STEP-8-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2022 | Very low |
| STEP-8-HEPATIC-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-8-PKprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-8-RENAL-IMPprogramme record | Semaglutide | Phase 1 | Reported | Phase 1 ascending dose | — | 2022 | Very low |
| STEP-TEENS-DDIprogramme record | Semaglutide | Phase 1 | Reported | Randomised crossover | — | 2022 | Very low |
page 12 of 30